METHODS: A total of 96 patients(96 eyes)with DME were classified as diffuse retinal thickening(DRT group, 35 eyes), cystoid macular edema(CME group, 33 eyes)and serous retinal detachment(SRD group, 28 eyes)according to the OCT. All patients were treated with intravitreal injection of 0.5mg(0.05mL)conbercept. The changes of best corrected visual acuity(BCVA), central foveal thickness(CFT), the injection times and vision improves eyes were compared between three groups after 1,3,6mo treatment.

RESULTS: After 6mo follow up, the BCVA of the three groups showed a significant downward trend(F_time=205.880, P_time<0.01), and there were significant differences among the three groups(F_group=3.472, P_group=0.042). The DRT group had the best BCVA after treatment. The CFT of the three groups showed a significant downward trend(F_time=392.994, P_time<0.01), and there were significant differences among the three groups(F_group=5.046, P_group=0.012). The reduction of CFT in the DRT group and CME group were better than that in the SRD group. The DRT group had the least injection times, and the highest proportion of vision improves eyes after 6mo follow up.

CONCLUSION: The intravitreal injection of conbercept could significantly improve the visual acuity and reduce the CFT of DME with different OCT patterns. And DRT is the most effective type with the least injection times.